How I treat Waldenström macroglobulinemia

Blood

Volumn 114, Issue 12, 2009, Pages 2375-2385

  Treon, Steven P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; COLD AGGLUTININ; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FAMCICLOVIR; FLUDARABINE; GANCICLOVIR; HEMOGLOBIN; IMMUNOGLOBULIN M; LENALIDOMIDE; NUCLEOSIDE ANALOG; PLACEBO; PREDNISONE; PREGABALIN; RITUXIMAB; THALIDOMIDE; VALACICLOVIR; VINCRISTINE;

ALOPECIA; ALTERNATIVE MEDICINE; AMYLOIDOSIS; ANAMNESIS; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLOOD EXAMINATION; BLOOD VISCOSITY; BONE MARROW; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYOGLOBULINEMIA; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DISEASE CONTROL; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG USE; FEBRILE NEUTROPENIA; HEMOGLOBIN BLOOD LEVEL; HEREDITY; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY CARCINOMA; LABORATORY TEST; LYMPHADENOPATHY; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOLOGY; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK; SALVAGE THERAPY; THROMBOCYTE COUNT; WALDENSTROEM MACROGLOBULINEMIA; MULTIMODALITY CANCER THERAPY;

COMBINED MODALITY THERAPY; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 70350490537     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-174359     Document Type: Review

References (92)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol. 2003;30(2):110-115. (Pubitemid 36506291)
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361-1392. (Pubitemid 24273002)
3. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. J Clin Oncol. 1999;155(1):257-265.
4. Merlini G, Farhangi M, Osserman EF. Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. Semin Oncol. 1986;13(3):350-365. (Pubitemid 17204714)
5. Farhangi M, Merlini G. The clinical implications of monoclonal immunoglobulins. Semin Oncol. 1986;13(3):366-379.
6. Marmont AM, Merlini G. Monoclonal autoimmunity in hematology. Haematologica. 1991;76(6):449-459.
7. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006;17(3):488-494.
8. McMaster ML, Csako G, Giambarresi TR, et al. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res. 2007;13(17):5063-5069. (Pubitemid 47502071)
9. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112(8):3052-3056.
10. Santini GF, Crovatto M, Modolo ML, et al. Waldenström macroglobulinemia: a role of HCV infection? Blood. 1993;82(9):2932. (Pubitemid 23318106)
11. Silvestri F, Barillari G, Fanin R, et al. Risk of hepatitis C virus infection, Waldenström's macroglobulinemia, and monoclonal gammopathies. Blood. 1996;88(3):1125-1126. (Pubitemid 26333344)
12. Leleu X, O'Connor K, Ho A, et al. Hepatitis C viral infection is not associated with Waldenstrom's macroglobulinemia. Am J Hematol 2006. Am J Hematol. 2007;82(1):83-84.
13. Treon SP, Hunter Z, Ciccarelli BT, et al. IgA and IgG hypogammaglobulinemia is a constitutive feature in most Waldenstrom's macroglobulinemia patients and may be related to mutations associated with common variable immunodeficiency disorder (CVID). Blood. 2008;112(11):Abstract 3749.
14. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):116-120. (Pubitemid 36506292)
15. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163-4170.
16. Pruzanski W, Shumak KH. Biologic activity of cold-reacting autoantibodies (first of two parts). N Engl J Med. 1977;297(11):538-542. (Pubitemid 8187089)
17. Pruzanski W, Shumak KH. Biologic activity of cold-reacting autoantibodies (second of two parts). N Engl J Med. 1977;297(10):583-589. (Pubitemid 8197338)
18. Menke MN, Feke GT, McMeel JW, Branagan A, Hunter Z, Treon SP. Hyperviscosity-related retinopathy in Waldenstrom's macroglobulinemia. Arch Ophthalmol. 2006;124(11):1601-1606.
19. Menke MN, Treon SP. Hyperviscosity syndrome. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: McGraw-Hill; 2007:937-941.
20. Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenström's macroglobulinemia. Semin Oncol. 2003;30(2):211-215. (Pubitemid 36506311)
21. Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology. 1987;37(9):1506-1514. (Pubitemid 17132332)
22. Garces-Sanchez M, Dyck PJ, Kyle RA, et al. Antibodies to myelin-associated glycoprotein (anti-MAG) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve. 2008;37(4):490-495.
23. Al-Lozi MT, Pestronk A, Choski R. A skeletal muscle-specific form of decorin is a target antigen for a serum IgM M-protein in a patient with a proximal myopathy. Neurology. 1997;49(6):1650-1654. (Pubitemid 28015133)
24. Owen RG, Barrans SL, Richards SJ, et al. Waldenström macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116(3):420-428. (Pubitemid 32851976)
25. San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):187-195.
26. Hunter ZR, Branagan AR, Manning R, et al. CD5, CD10, CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005;5(4):246-249. (Pubitemid 40614235)
27. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100(8):2996-3001.
28. Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenstrom's macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136(1):80-86. (Pubitemid 44912591)
29. Leleu X, Hunter ZR, Xu L, et al. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom macroglobulinemia. Br J Haematol. 2009;145(1):59-63.
30. Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenstrom's macroglobulinemia. Proceedings of the 5th International Workshop on Waldenstrom's macroglobulinemia, Stockholm, Sweden, 2008 [Abstract 125].
31. Avet-Loiseau H, Garand R, Lode L, Robillard N, Bataille R. 14q32 translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):153-155. (Pubitemid 36506299)
32. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6(5):380-383.
33. Menke MN, Feke GT, McMeel JW, Treon SP. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):100-103.
34. Treon SP, Gertz MA, Dimopoulos MA, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. Blood. 2006;107(9):3442-3446.
35. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27(1):120-126.
36. Thomas S, Hosing C, Delasalle KB, et al. Success rates of autologous stem cell collection in patients with Waldenstrom's macroglobulinemia. Proceedings of the 5th International Workshop on Waldenstrom's macroglobulinemia, Stockholm, Sweden, 2008 [Abstract].
37. Leleu XP, Manning R, Soumerai JD, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27(2):250-255.
38. Leleu X, Tamburini J, Roccaro A, et al. Balancing risk versus benefit in the treatment of Waldenstrom's macroglobulinemia patients with nucleoside analogue based therapy. Clin Lymphoma Myeloma. 2009;9(1):71-73.
39. Rakkhit R, Delasalle KB, Gavino MB, et al. Incidence of transformation to large cell lymphoma and to second malignancies in symptomatic patients with Waldenstrom's macroglobulinemia (WM) treated with cladribine (2-CdA) combination induction. Blood. 2008;112(11): Abstract 3065.
40. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830-3835.
41. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007;13(11):3320-3325. (Pubitemid 46944918)
42. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24(13):2105-2112. (Pubitemid 46622122)
43. Ghobrial IM, Matous J, Padmanabhan S, et al. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom's macroglobulinemia. Blood. 2008;112(11):Abstract 832.
44. Agathocleous A, Rule S, Johnson P. Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab in patients with follicular lymphoma, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Blood. 2007;110(11):Abstract 2559.
45. Treon SP, Hunter Z, Branagan A. CHOP plus rituximab therapy in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2005;5(4):273-277. (Pubitemid 40614242)
46. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone, rituximab and cyclophosphamide. J Clin Oncol. 2007;25(22):3344-3349. (Pubitemid 47325621)
47. Buske C, Hoster E, Dreyling MH, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153-161.
48. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):62-66.
49. Weber DM, Dimopoulos MA, Delasalle K, et al. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):243-247. (Pubitemid 36506318)
50. Treon SP, Branagan AR, Ioakimidis L, et al. Long term outcomes to fludarabine and rituximab in Waldenstrom's macroglobulinemia. Blood. 2009;113(16):3673-3678.
51. Tam CS, Wolf MM, Westerman D, et al. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2005;6(2):136-139.
52. Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood. 2009;113(4):793-796.
53. Tedeschi A, Alamos SM, Ricci F, et al. Fludarabine-based combination therapies for Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):67-70.
54. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004;15(10):1481-1483. (Pubitemid 39409737)
55. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M "flare" after rituximab therapy in patients with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101(11):2593-2598. (Pubitemid 39532289)
56. Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Am J Hematol. 2004;77(4):329-330.
57. Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. J Clin Oncol. 2006;24(1):E3.
58. Broglio L, Lauria G. Worsening after rituximab treatment in anti-MAG neuropathy. Muscle Nerve. 2005;32(3):378-379. (Pubitemid 41232625)
59. Kilidireas C, Anagnostopoulos A, Karandreas N, et al. Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma. 2006;47(5):859-864. (Pubitemid 43840641)
60. Izzedine H, Bourry E, Amrouche L, et al. Immunoglobulin M 'flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia. Int J Hematol. 2009;89(2):218-222.
61. Nichols GL, Savage DG. Timing of rituximab/fludarabine in Waldenstrom's macroglobulinemia may avert hyperviscosity. Blood. 2004;104(11):Abstract 4612.
62. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom's macroglobulinemia. Blood. 2008;112(12):4452-4457.
63. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009;15(1):355-360.
64. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317-324. (Pubitemid 30056420)
65. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother. 2001;24(3):272-279. (Pubitemid 32479719)
66. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45(10):2047-2055. (Pubitemid 39232853)
67. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol. 2002;20(9):2327-2333.
68. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005;16(1):132-138. (Pubitemid 40124490)
69. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in Fc-RIIIA (CD16) receptor expression are associated with clinical responses to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23(3):474-481. (Pubitemid 46224224)
70. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74(4):485-489. (Pubitemid 36379372)
71. Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst. 2007;12(2):102-107. (Pubitemid 46906332)
72. Dalakas MC, Rakocevic G, Salajegheh MD, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286-293.
73. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295-3301. (Pubitemid 44794222)
74. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570-1575. (Pubitemid 46733084)
75. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica. 2005;90(12):1655-1657. (Pubitemid 41814990)
76. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91(7):929-934. (Pubitemid 44023146)
77. Treon SP, Kelliher A, Keele B, et al. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol. 2003;30(2):248-252. (Pubitemid 36506319)
78. Santos DD, Hatjiharissi E, Tournilhac O, et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006;6(6):478-483.
79. Hunter ZR, Boxer M, Kahl B, et al. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079. Proc Am Soc Clin Oncol. 2006;24(33):Abstract 7523.
80. Owen RG, Rawstron AC, Osterborg A, et al. Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia. Blood. 2003;102(11):644a.
81. Kyriakou H, on behalf of the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Haematopoietic stem cell transplantation for Waldenstrom's macroglobulinemia. Proceedings of the 5th International Workshop on Waldenstrom's macroglobulinemia, Stockholm, Sweden, 2008 [Abstract 146].
82. Maloney D. Evidence for GVWM following miniallo in Waldenstrom's macroglobulinemia. Proceedings of the 5th International Workshop on Waldenstrom's macroglobulinemia, Stockholm, Sweden, 2008 [Abstract 147].
83. Gertz MA, Hayman SR, Buadi FK. Transplantation for IgM amyloidosis and IgM myeloma. Clin Lymphoma Myeloma. 2009;9(1):77-79.
84. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the firstline treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL). Blood. 2008;112(11):Abstract 2596.
85. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenstrom's macroglobulinemia: first interim results of a randomized phase III study of the Studygroup Indolent Lymphomas (StiL). Proceedings of the 5th International Workshop on Waldenstrom's macroglobulinemia, Stockholm, Sweden, 2008 [Abstract 139].
86. Hatjiharissi E, Mitsiades CS, Ciccarelli B, et al. Comprehensive molecular characterization of malignant and microenvironmental cells in Waldenstrom's macroglobulinemia by gene expression profiling. Blood. 2007;110(11):Abstract 3174.
87. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007;110(11):4417-4426.
88. Ghobrial IM, Chuma S, Sam A, et al. Phase II trial of the mTOR inhibitor RAD001 in relapsed and/or refractory Waldenstrom macroglobulinemia: the Dana Farber Cancer Institute Experience. Blood. 2008;112(11):Abstract 1011.
89. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):127-131. (Pubitemid 36506294)
90. Varghese AM, Rawstron AC, Ashcroft J, et al. Assessment of bone marrow response in Waldentrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):53-55.
91. HoA, Leleu X, Hatjiharissi E, et al. CD27-CD70 interactions in the pathogenesis ofWaldenstrom's macroglobulinemia. Blood. 2008;112(12):4683-4689.
92. Ciccarelli BT, Yang G, Hatjiharissi E, et al. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab induced IgM flare, as well as plasmapheresis in patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):56-58.